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Summary 
Objective: To review the topic of alpha-1 antitrypsin (AAT) deficiency. 
Method: Narrative literature review. 
Results: Much work has been carried out on this condition with many questions being 
answered but still further questions remain.  
Discussion and Conclusions: AAT deficiency is an autosomal co-dominantly 
inherited disease which affects the lungs and liver predominantly. The clinical 
manifestations, prevalence, genetics, molecular pathophysiology, screening and 
treatment recommendations are summarised in this review. 
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Introduction 
 AAT deficiency is a genetic disorder that affects an approximated 
3.4 million individuals worldwide, when individuals with the ZZ, SZ or SS phenotype 
are included (1). This condition is clinically characterised by early-onset emphysema 
and liver disease.  
AAT deficiency was first documented by Laurell and Eriksson in 1963 (2). 
They carried out a painstaking review of 1500 serum protein electrophoresis gels in 
which the band for the ǩ1 was absent. Three out of five of these patients developed 
emphysema at a young age. Since that time much work has been done on AAT 
deficiency elucidating the genotypes and the phenotypes of the condition, the clinical 
variation in symptoms and signs, the method of diagnosis and of screening and the 
possibilities for treatment. Many questions have been answered but with these many 
more questions surface. 
 
Prevalence of AAT deficiency 
AAT deficiency is a genetic cause of Chronic Obstructive Pulmonary Disease 
(COPD). The frequency of AAT deficiency can only be estimated. In one study of 
965 patients with COPD who were screened for AAT deficiency 1.9% were shown to 
have the disease (3). Extrapolating from the National Health Information Survey in 
the USA which estimates that 3.1 million Americans have emphysema this would 
suggest that in 59,000 of these patients the emphysema is caused by AAT deficiency. 
Under-recognition of AAT deficiency is a problem. When given a questionnaire 
addressing the number of doctors seen for symptoms attributable to AAT deficiency 
and the onset of AAT deficiency-related symptoms the 300 patients studied reported a 
mean delay between first symptom and initial diagnosis of the disorder of 7.2 years 
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(4). The delay in initial diagnosis was shown in this study to be associated with 
adverse outcomes for the patients in relation to psychosocial effects. Other 
consequences include slowed opportunities to offer specific counselling and therapy. 
More recently this delay has decreased slightly to a mean of 5.6 years (5) 
demonstrating still further room for improvement. 
 
Clinical Manifestations 
The clinical disease associated with AAT deficiency can present in a number 
of ways but the most frequent organs affected are the lung and the liver. In the lung, 
emphysema is the most common manifestation. The emphysema associated with AAT 
deficiency tends to be early in onset (i.e. in the fourth and fifth decades), panacinar in 
pathology and disproportionate in its effect on the lung bases (compared to the more 
apical distribution in AAT replete patients) (6-8). Evidence for the association of 
bronchiectasis with AAT deficiency is mixed. Larsson originally noted bronchiectasis 
in 11.3% of 246 patients with the ZZ phenotype (9). The NHLBI registry reported 
bronchiectasis in only 2% of 1129 participants (10) and in a case-control study 
Cuvelier and colleagues recorded no excess frequency of AAT deficiency in patients 
with bronchiectasis compared with those without bronchiectasis (11). A more recent 
study characterising the computed tomographic phenotype of patients with AAT 
deficiency found that clinically significant bronchiectasis occurred in 27% of the 
patients studied, greater than previously recognised (12). 
After the lung the liver is the next most commonly affected organ in AAT 
deficiency. In a Swedish population-based screening study of 200,000 neonates, 22 
(18%) of 120 babies with the Z allele had evidence of some liver dysfunction over 
follow-up to the age of 6 months, including obstructive jaundice (12%) and minor 
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abnormalities (7%) (13). When liver dysfunction is present the risk of progressing to 
liver cirrhosis was estimated to be 50%; 25% died within the first decade of life and 
2% developed cirrhosis later in childhood (14). Larsson’s study followed 246 patients 
with the Z mutation for up to 11 years and found liver disease in 12.2% (cirrhosis in 
11.8%, neonatal hepatitis in 0.4%, and hepatoma in 3.3%) (9). Finally Eriksson’s 
analysis of 38 post-mortem examinations from among 58 decedents with expected 
AAT deficiency in Malmo, Sweden observed cirrhosis in 34% (n=14), in whom 
cirrhosis was suspected during life in 64% (15). The established association of Z 
mutation AAT deficiency with liver disease has lead to the recommendation for 
screening all neonates, children and adults with unexplained liver disease for this 
condition (16). Low AAT levels can lead to a diagnosis of AAT deficiency, but there 
is no correlation between AAT level and risk of liver disease. The risk of cirrhosis in 
SZ patients is now established. The S variant is known to have an increased 
susceptibility to polymerization, although this is marginal compared with the more 
conformationally unstable Z variant (17). There has been speculation that the two may 
interact to produce cirrhosis, but this has never been demonstrated experimentally. 
Panniculitis is a skin condition associated with AAT deficiency. This 
condition however is not frequent with an occurrence of about 1 in 1000 patients with 
AAT deficiency (18). 
Vasculitis is another of the less frequently occurring diseases associated with 
AAT deficiency. An over-representation of abnormal AAT phenotypes in people with 
antiproteinase 3 antibody-positive (i.e., c-ANCA-positive) vasculitis in case series has 
established an association between the two conditions. Specifically, prevalence of the 
Z allele among c-ANCA positive individuals was 5.6-17.6%, which exceeds by 
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threefold to ninefold the prevalence in healthy people (16, 19). The ATS/ERS 
statement also recommends testing for all adults with c-ANCA-positive vasculitis. 
The precise risk of developing emphysema in people with the ZZ phenotype is 
not known. Tobin et al assessed the risk of developing emphysema in ZZ siblings of 
index cases (20). They found that emphysema was present radiographically in 90% of 
smokers compared with 65% of non-smokers. A Swedish study found that in adults 
homozygous for the Z allele only 29% of never smokers and 10% of ever smokers 
were healthy (21). The remainder had lung disease. Findings from post-mortems 
reported in the same study and of CT studies reported by Parr et al suggest that only 
14-20% of Z homozygotes were free of COPD (22). The most common cause of death 
in patients with AAT deficiency is respiratory failure (accounting for 50-72% of 
deaths) followed by liver cirrhosis (10-13%) (23, 24). The observed overall yearly 
mortality rate ranges from 1.7% to 3.5% (9, 23-26). Factors found to be associated 
with increased mortality include older age, lower education, lower FEV1 predicted, 
lung transplant, and not receiving augmentation therapy (23). In another study only 
age and CT assessment of proportion of emphysema predicted respiratory and all-
cause mortality (24). 
There is also an association of the Z allele of AAT with asthma (27, 28), 
pancreatitis (29) and vascular aneurysms (30, 31). Associations with some 
neuropsychological conditions have also been suggested. AAT S or Z polymorphisms 
were shown to be present in 25% of persons with anxiety disorder and 42% of persons 
with bipolar disorder compared to 10% of a control group without pre-existing 
affective disorder (32). A recent study comments on how low serum AAT in family 
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members of individuals with autism correlates with PiMZ genotype (33) and another 
study suggests a link between the Z allele and “intense creative energy” (34).  
Genetics  
AAT deficiency is an autosomal co-dominant condition. The AAT protein is 
encoded by the SERPINA1 gene, previously known as the protease inhibitor (PI) 
gene, the locus for which is located on chromosome 14q32.1 (35-39). This gene for 
AAT has been cloned and sequenced (40, 41). The SERPINA1 gene is 12.2kb in 
length with seven exons and six introns.  
The SERPINA1 gene or PI locus is highly polymorphic with approximately 
123 single nucleotide polymorphisms (SNPs) listed (42). Differences in speed of 
migration of different protein variants on gel electrophoresis has been used to identify 
the PI phenotype, and these differences in migration relate to variations in protein 
charge resulting from amino acid alterations (figure 1) (43). The M allele results in a 
protein with a medium rate of migration; the Z form of the protein has the slowest rate 
of migration. Some individuals inherit null alleles that result in protein levels that are 
not detectable. Individuals with a Z pattern on serum isoelectric focusing are referred 
to as phenotype PIZ (encompassing both PIZZ and PIZnull genotype variants). The S 
variant occurs at a frequency of 0.02-0.03 and is associated with mild reductions in 
serum AAT levels. The Z variant is associated with a severe reduction in serum AAT 
levels. The most common alleles are the M variants with allele frequencies of greater 
than 0.95 and normal AAT levels. 
The Z allele (Glu342Lys) causes the most severe plasma deficiency and is 
most prevalent in southern Scandinavia and the northwest European seaboard, with 
gene frequencies reducing toward the south and east of the continent (44, 45). In 
contrast, the S allele (Glu264Val) causes only mild plasma deficiency and is most 
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common in southern Europe and becomes less frequent as one moves northeast. The 
frequencies of the Z allele in the United States are similar to the lowest frequencies in 
Europe, but the S allele is more common than in northern Europeans. AAT deficiency 
is infrequent in the Asian, African and Middle Eastern populations (1) . 
Even in patients with severe AAT deficiency, the development, manifestations 
and progression of COPD are highly variable, which suggest that modifier genes, 
environmental exposures, and the combined effect of gene and environmental factors 
may be relevant to disease expression. The altered AAT protein is the product of a 
single gene, but the disease phenotype is probably a result of many genes. Genetic 
modifiers of lung disease in AAT deficient individuals may also provide insight into 
COPD unrelated to AAT deficiency. 
The AAT protein, that the SERPINA1 gene gives rise to, is 52 kDa and 
includes 394 amino acids with the active site of the enzyme inhibitor at methionine 
358. It is an antiprotease. Initially labelled “antitrypsin” it was later found to have a 
much higher affinity for the protease neutrophil elastase (NE). In its activity inhibiting 
NE, AAT plays a pivotal role in the delicate protease-antiprotease balance.  
The molecular defect in the Z allele is a substitution of a lysine for a glutamic 
acid at position 342 due to a single base alteration in the gene. The low protein levels 
result from polymerisation of the protein within the hepatocyte endoplasmic 
reticulum, with subsequent reduction in serum levels due to intracellular accumulation 
(46). In ZZ homozygous patients the plasma AAT level is of 10% of the normal M 
allele and 60% in the MZ heterozygote (50% from the M allele and 10% from the Z 
allele).  
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Molecular pathophysiology 
The AAT molecule is an acute phase glycoprotein (47). This is synthesised 
and secreted mainly in the liver by hepatocytes (48, 49) but also synthesised by and 
secreted from macrophages (50), intestinal (51) and bronchial epithelial cells (52). It 
not only inhibits pancreatic trypsin (53) but also it many other proteinases including 
neutrophil elastase, cathepsin G (54) and proteinase 3 (55). 
Crystal structures have shown that AAT is composed of three  sheets (A-C) 
and an exposed mobile reactive loop that presents a peptide sequence as a 
pseudosubstrate for the target proteinase (56-61). The critical amino acids within this 
loop are the PI-PI’ residues, methionine serine, as these act as “bait” for neutrophil 
elastase (62). After docking, the enzyme cleaves the P1-P1’ peptide bond of AAT and 
the proteinase is inactivated by a mousetrap action that swings it from the upper to the 
lower pole of the protein in association with the insertion of the reactive loop as an 
extra strand in -sheet A (63-68). This altered product of the AAT bound to its 
substrate is recognised by hepatic receptors and cleared from circulation (69). The 
conformational change that underlies the clinical disease of AAT deficiency interferes 
with the processing of this altered protein in the hepatocyte.  (Figure 2) 
 
Molecular Pathology of the Liver Disease 
Current evidence tells us that the liver disease in Z variant AAT deficiency is 
caused by an accumulation of the abnormal protein in the liver rather than a plasma 
deficiency. Strong support is provided by the fact that null alleles, which produce no 
AAT, are not associated with cirrhosis (70). In addition to this, overexpression of 
ZAAT in animal models results in liver damage (71, 72). 
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The presence of the Z mutation causes a conformational change in the AAT 
molecule. The  sheet A opens leaving it susceptible to interaction with another AAT 
molecule to form a dimer or following interaction with further AAT molecules to 
form a polymer (57, 73-75). These polymers get trapped in the endoplasmic 
reticulum. The experimental proof of this was in work from Lomas et al showing 
polymer formation when the purified plasma ZAAT is incubated under physiological 
conditions (74). These polymers were also found in inclusion bodies in the liver of a Z 
heterozygotic patient (74, 76) and in hepatic cell lines expressing the Z variant (77). 
In work on Xenopus oocyte cells, blocking the polymerisation with point mutations 
was shown to increase secretion of mutants of AAT (78). The Z mutation causes most 
of the unstable protein to form polymers. 
The method by which the hepatocytes deal with the polymers has been the 
source of much study. Trimming asparagine linked oligosaccharides target ZAAT 
polymers into an efficient non-proteosomal disposal pathway (79-81). The 
proteosome pathway has been shown to be important in some hepatic (82) and 
extrahepatic mammalian cell lines (83, 84). Retained ZAAT stimulates an autophagic 
response in the hepatocyte (85, 86). 
The endoplasmic reticulum has a very important role in protein folding and the 
handling of misfolded proteins. Specific signalling pathways (87) and effector 
mechanism have evolved to deal with the temporal and developmental variation in the 
ER load. The upstream signal that activates these pathways is referred to as ER stress 
and is defined functionally as an imbalance between the load of proteins facing the 
ER and the organelle’s ability to process that load. The cellular response to ER stress 
has four main functional components: ER overload response (EOR), the unfolded 
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protein response (UPR) (88), a decrease in protein synthesis, and programmed cell 
death (89). 
There is a great heterogeneity of liver disease in ZAAT patients. Experimental 
work shows effects with an increase in temperature, concentration of the substrates 
for polymerisation (73, 74) and genetic factors (90, 91). Results regarding temperature 
vary in different studies. One study shows no increase in intracellular ZAAT in 
response to raised temperatures (92) but further work in a Drosophila model of AAT 
deficiency show a clear temperature dependence of polymerisation in vivo (93).  
 Cigarette smoking is the most important factor in the development of the lung 
disease associated with AAT deficiency (94, 95). It is in the lung that the imbalance in 
the protease antiprotease balance is seen to have a major effect. In the case of Z 
variant AAT deficiency there is less AAT in the lung (96). The AAT that is present is 
5 times less effective than normal AAT (97-100). The residual AAT is susceptible to 
inactivation by oxidation of the P1 methionine residue by free radicals from 
leukocytes or direct oxidation by cigarette smoke (54, 101-103). The Z AAT also 
favours the formation of polymers in the lung (104). ZAAT deficient patients have 
excess neutrophils in lavage fluid (105) and in tissue sections of the lung (106) 
possibly related to the chemoattractant effect of an excess of leukotriene B4 (LTB4) 
and interleukin (IL) -8 (107, 108) and the polymers themselves (109). These 
circumstances of unopposed proteolytic enzyme activity and an increase in 
inflammatory conditions cause the trademark emphysema of this disease.  
 
Screening 
Recommendations for screening for AAT deficiency have been clarified with 
publication of the American Thoracic Society /European Respiratory Society 
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statement on diagnosis and management of the condition (16). The four main benefits 
of early detection of AAT deficiency are 1. smoking prevention/cessation 2. 
minimizing the hazards of occupational respiratory pollutants 3. allowing 
opportunities to receive augmentation therapy and 4. the potential for family planning 
and guided genetic counselling/testing (110). Symptomatic individuals may require 
life-long therapy, and early detection may reduce the clinical and economic burdens 
of progressive lung deterioration (111). 
Smoking cessation advice has proven to be effective in patients with AAT 
deficiency. Follow-up of the original patients from the 1970s AAT deficiency 
screening program in Sweden who are now 30 years of age has shown that smoking is 
less common in them than in control subjects (112). Further studies showed that 
following screening the subsequent provision of information and advice prevented the 
majority of affected adolescents from smoking (113, 114). 
It is perceived that knowledge of AATD diagnosis should aid affected 
individuals in their occupational choices, allowing them to avoid exposure to 
environmental agents (e.g. avoiding careers in steel-manufacturing.) 
Augmentation therapy is available and will be discussed in more detail in the next 
section. Early diagnosis with screening programs allows this to be instigated while 
lung function is preserved. 
The impact of diagnosis through screening has multiple implications for the 
individual. There is a psychological impact of the diagnosis which can be positive for 
patients satisfied to have found a reason for their symptoms but may be negative with 
concerns for the future. The ethics of screening family members raises a challenge 
especially in respect to minors who have the decision made for them. The 
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consequences of a confirmed diagnosis of AATD include possible discrimination for 
example by employers and insurers. 
Screening with genotyping is recommended. AAT levels may be less 
expensive but establishing the genotype gives more information about the likelihood 
of developing clinical consequences of the disease.  
 
Treatment of AAT deficiency 
As AAT deficiency results in COPD the medical therapy for COPD also 
applies to AAT deficiency. These have been outlined in previous published guidelines 
of the ATS, BTS and the GOLD guidelines (115-117). Most patients with AAT 
deficiency and obstructive lung disease find symptomatic benefit from 
bronchodilators even though objective bronchodilator responsiveness may be lacking. 
Those with proven bronchial hyperreactivity may be given an inhaled steroid with the 
presumption that a decrease in bronchial inflammation may reduce the loss in FEV1 
over time. A study has suggested benefit of inhaled steroids in some patients with 
AAT deficiency-related lung disease, although it is not clear which patients benefit 
(118). Antibiotics are recommended for treatment of exacerbations triggered by 
bacterial infections. Portable oxygen is recommended for those who desaturate with 
exercise but otherwise long-term oxygen therapy is only recommended for those with 
severe hypoxaemia. This should be prescribed in concordance with the ATS and ERS 
criteria (115, 116). Oral steroids can be cautiously considered in patients with a clear 
asthmatic component to their disease and long term use should be avoided. Co-
morbidities that accompany COPD outside the setting of AAT deficiency should 
always be borne in mind. These include depression, anxiety and malnutrition. 
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Pulmonary rehabilitation can offer benefit; improving endurance, reducing dyspnoea 
and reducing number of hospitalisations (119).  
Treatment specific to AAT deficiency is centred on AAT augmentation 
therapy. There are four potential treatment options (1) intravenous human plasma-
derived augmentation therapy, (2) augmentation therapy by inhalation, (3) 
recombinant AAT augmentation therapy, and (4) synthetic elastase inhibition. 
 
Intravenous human plasma-derived augmentation therapy 
Since the early 1980s intravenous administration of purified human AAT 
concentrate was shown to increase lung levels of AAT in AAT deficient patients (96, 
120). Patients receiving once weekly IV doses increased the antineutrophil elastase 
capacity in lung epithelium lining fluid by 60-70%. A purified preparation was 
manufactured and shown to be biologically active (121-123) and this lead to the US 
Food and Drug Administration approval in the United States in 1988. Randomised 
placebo-controlled trials evaluating the effect of IV AAT replacement therapy in 
attenuating the development of emphysema are lacking with only one published 
(124). Recommendations on the use of augmentation therapy is based on the 
ATS/ERS guidelines (16). 
Decline in FEV1 has been shown to be lower in patients treated with iv 
augmentation therapy compared with untreated patients (125, 126). In comparing the 
different degrees of functional impairment, a significant effect of the treatment was 
demonstrated only in the group of patients with an initial FEV1 of 31-65% predicted. 
This non-randomised study showed that weekly infusion of human AAT in patients 
with moderately reduced lung function may slow the annual decline in FEV1. In a 
similar study from the NHLBI Registry the mortality rate was lower in those 
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receiving augmentation therapy as compared with those not receiving therapy and 
mean FEV1 decline was only slowed in the subgroup of patients with moderate 
emphysema. The only randomised trial was small with only 58 patients. The number 
of patients limited the only significant finding to being an attenuation in the loss of 
lung density in the treated group (124).  
 
Augmentation therapy by inhalation 
Aerosol application of AAT in patients with AAT deficiency increases AAT 
concentration and anti-elastase activity in the lower respiratory tract in a dose-
dependent fashion (127).  Preliminary data suggest that one or twice daily 
administration of aerosolized AAT may produce sustained anti-elastase protection of 
the lungs.  
 
Recombinant AAT augmentation therapy and synthetic elastase inhibition  
A number of recombinant forms of AAT have been developed as well as 
recombinant secretory leukoprotease inhibitor (128) and several synthetic low 
molecular weight elastase inhibitors are being evaluated but their clinical efficacy and 
safety have not been reported.  
In summary the available studies indicate a lowered overall mortality and a 
slower rate of FEV1 decline in augmentation therapy recipients with FEV1 values of 
35-65% of predicted. 
 
Lung transplantation may be recommended for some patients with end-stage 
lung disease. Due to limitations on available donor lungs single lung transplant is 
more common despite the fact that outcome has been shown to be better in patient 
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who receive double lung transplant. Approximately 12% of all lung transplant 
operations for emphysema are due to AAT deficiency (129). Five year survival rates 
following lung transplant is approximately 50% with bronchiolitis obliterans being the 
major cause of death post-transplant (130).  
 
Lung volume reduction surgery  
Lung volume reduction surgery (LVRS) improves exercise capacity and 
relieves dyspnoea in patients with usual emphysema but the story is less clear in AAT 
deficiency. One study showed a benefit to bilateral LVRS in AAT deficient patients 
with emphysema but functional measurements (except 6 minute walk test) returned to 
baseline at 6 to 12 months (131). LVRS was not recommended in the ATS/ERS 
guidelines for management of AAT deficiency in their 2003 statement. 
 
Future Research 
A large volume of research continues in the field of AAT deficiency. Three 
examples are in the field of candidate modifier genes, anti-inflammatory proteins and 
potential synthetic antiproteases. Although the gene responsible for the 
conformational change in AAT has been identified variations in the presentation of 
patients strongly suggests the role for candidate modifier genes. An example of a 
potential modifier is Selenoprotein S / SEPS1. This selenoprotein has been shown to 
decrease manifestations of ER stress in an in vitro model of Z-variant AAT deficiency 
(132). 
Other anti-inflammatory therapies will continue to be investigated in this 
disease. Recent work showed that bronchoalveolar lavage (BAL) fluid from patients 
with AAT deficiency containing free neutrophil elastase had increased cathepsin B 
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and matrix metalloproteinase-2 (MMP2) activities compared with BAL fluid from 
healthy volunteers. AAT augmentation therapy to AAT-deficient individuals reduced 
cathepsin B and MMP-2 activity in BAL fluid in vivo. Furthermore, AAT-deficient 
patients had higher levels of secretory leukocyte peptidase inhibitor (SLPI) and 
lactoferrin after AAT augmentation therapy suggesting a novel role for AAT 
inhibition of NE-induced upregulation of MMP and cathepsin expression both in vitro 
and in vivo (133). 
 
Conclusion 
AAT deficiency is an under diagnosed disease causing much morbidity and 
mortality in those affected. Much has been elucidated about the genetics and the 
molecular pathophysiology and potential therapies of this condition. Further research 
continues to investigate the varying presentations between different patients with 
AAT deficiency and the full effect of AAT and the body’s response to it. 
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